

## **STIC Biotechnology Systems Branch**

### **RAW SEQUENCE LISTING** **ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/553,906C

Source: IFWO

Date Processed by STIC: 11/16/06

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 4.4.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

**<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>**

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):  
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/10/06

## Raw Sequence Listing Error Summary

### ERROR DETECTED

### SUGGESTED CORRECTION

SERIAL NUMBER:

10/553,906C

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 ☐ Wrapped Nucleics  
Wrapped Aminos      The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor **after** creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 ☐ Invalid Line Length      The rules require that a line **not exceed** 72 characters in length. This includes white spaces.
- 3 ☐ Misaligned Amino  
Numbering      The numbering under each 5<sup>th</sup> amino acid is misaligned. Do **not** use tab codes between numbers; use **space characters**, instead.
- 4 ☒ Non-ASCII      The submitted file was **not** saved in ASCII(DOS) text, as **required** by the Sequence Rules. **Please ensure your subsequent submission is saved in ASCII text.**
- 5 ☐ Variable Length      Sequence(s) ☐ contain n's or Xaa's representing more than one residue. **Per Sequence Rules, each n or Xaa can only represent a single residue.** Please present the **maximum** number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 ☐ PatentIn 2.0  
"bug"      A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) ☐. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.**
- 7 ☐ Skipped Sequences  
(OLD RULES)      Sequence(s) ☐ missing. If intentional, please insert the following lines for **each** skipped sequence:  
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
This sequence is intentionally skipped  
  
Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to **include** the skipped sequences.
- 8 ☐ Skipped Sequences  
(NEW RULES)      Sequence(s) ☐ missing. If **intentional**, please insert the following lines for **each** skipped sequence.  
<210> sequence id number  
<400> sequence id number  
000
- 9 ☐ Use of n's or Xaa's  
(NEW RULES)      Use of n's and/or Xaa's have been detected in the Sequence Listing.  
Per 1.823 of Sequence Rules, use of <220>-<223> is **MANDATORY** if n's or Xaa's are present.  
In <220> to <223> section, please explain location of **n** or **Xaa**, and which residue **n** or **Xaa** represents.
- 10 ☐ Invalid <213>  
Response      Per 1.823 of Sequence Rules, the only **valid** <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is **required** when <213> response is Unknown or is Artificial Sequence
- 11 ☒ Use of <220>      Use of <220> to <223> is **MANDATORY** if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 ☐ PatentIn 2.0  
"bug"      Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 ☐ Misuse of n/Xaa      "n" can **only** represent a single nucleotide; "Xaa" can **only** represent a single amino acid



IFWO

## RAW SEQUENCE LISTING

DATE: 11/16/2006

PATENT APPLICATION: US/10/553,906C

TIME: 11:42:14

Input Set : A:\PTO.SS.txt

Output Set: N:\CRF4\11162006\J553906C.raw

3 <110> APPLICANT: Skanemeier AB  
 5 <120> TITLE OF INVENTION: NEW ENZYME AND ITS USE  
 7 <130> FILE REFERENCE: 75086  
 C--> 9 <140> CURRENT APPLICATION NUMBER: ~~US/10/553,906C~~  
 C--> 9 <141> CURRENT FILING DATE: 2005-10-21  
 9 <150> PRIOR APPLICATION NUMBER: US 60/320,139  
 10 <151> PRIOR FILING DATE: 2003-04-24  
 12 <150> PRIOR APPLICATION NUMBER: US 60/481,598  
 13 <151> PRIOR FILING DATE: 2003-11-05  
 15 <160> NUMBER OF SEQ ID NOS: 18  
 17 <170> SOFTWARE: PatentIn version 3.2

Does Not Comply  
 Corrected Diskette Needed

## ERRORED SEQUENCES

690 <210> SEQ ID NO: 18  
 691 <211> LENGTH: 31  
 692 <212> TYPE: DNA  
 693 <213> ORGANISM: Unknown  
 695 <220> FEATURE:  
 696 <223> OTHER INFORMATION: Artificial  
 698 <400> SEQUENCE: 18  
 699 acgtcgactt accagcacca taacagccaa g  
 E--> 708 1

pls  
 delete

✓ Same  
 error  
 in Seq 5, 10-15,  
 17.

Artificial

Invalid  
 Response

Give source of  
 genetic  
 material.

31

(See item #11 on error  
 Summary sheet.)

← This is Not the  
 invention title in  
 the official  
 U.S. Application.  
 (See pg. 3)

**VERIFICATION SUMMARY**

PATENT APPLICATION: US/10/553,906C

DATE: 11/16/2006

TIME: 11:42:16

Input Set : A:\PTO.SS.txt

Output Set: N:\CRF4\11162006\J553906C.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application No  
L:9 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:238 M:283 W: Missing Blank Line separator, <400> field identifier  
L:401 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:900  
L:708 M:254 E: No. of Bases conflict, this line has no nucleotides.

**AMENDMENTS TO THE SPECIFICATION:**

On page 1, before line 1, please insert:

-- Title of the Invention--

On page 1, please amend line 1 as follows:

~~NEW ENZYME AND ITS USE~~ Human Alkaline Sphingomyelinase and use thereof

*Applicant must  
change 21207  
response to  
this.*

On page 1, after line 1, please insert:

--Cross Reference to Related Applications

This application is a national stage application of International Application PCT/SE2004/000628, filed April 23, 2004, designating the United States of America, which claims the benefit of Provisional Patent Application No. 60/320,139, filed April 24, 2003 and Provisional Patent Application No. 60/481,598, filed November 5, 2003.

Field of the Invention--

Please replace the existing abstract with the following, which also follows on a separate sheet at the conclusion of this submission:

-- An isolated human alkaline sphingomyelinase (Alk-Smase) or a variant thereof is capable of hydrolysing sphingomyelin. Methods are provided for isolating human Alk-Smase and for preparing human recombinant Alk-Smase. Further methods are provided for the use of the enzyme for the treatment of colon cancer.--